Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse maintenance in pediatric ADHD
NCT00784654Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Jan 2009; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00784654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784654.